Litigation Details for BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. (D.N.J. 2017)

BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. (D.N.J. 2017)

Docket		Date Filed	2017-12-15
Court	District Court, D. New Jersey	Date Terminated	2020-01-07
Cause	15:1126 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	6,803,046
Link to Docket	External link to docket

Details for BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-15				External link to document
2017-12-14	1	Exhibit US Patent 6,803,046	DIAGNOSTICS INC.. (Attachments: # 1 Exhibit US Patent 6,803,046)(KAO, HUAI-HUNG) Modified on 12/15/2017 (eu…December 2017 7 January 2020 3:17-cv-13151 Patent None District Court, D. New Jersey	External link to document
2017-12-14	85	Memorandum	concerning United States Patent No. 6,803,046 (the “046 Patent”). The ‘046 Patent is listed to market and…eight amino acids bound together. (‘046 Patent at 1:9-16). The patent also claims five other ingredients:…It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the invention to which …invention. (‘046 Patent at 11:29-63 (emphasis added)). In addition, example 3 of the patent indicates that…parties dispute the meaning of three terms in the patent: (1) buffer; (2) surfactant/solubilizer; and (3	External link to document

BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC. | 3:17-CV-13151 LITIGATION ANALYSIS

Last updated: February 19, 2026

This analysis summarizes and evaluates the patent litigation between Bracco Diagnostics Inc. and Maia Pharmaceuticals, Inc. concerning diagnostic imaging agents. The case involves allegations of patent infringement and invalidity.

WHAT ARE THE CORE DISPUTES IN THIS LITIGATION?

The central dispute in Bracco Diagnostics Inc. v. Maia Pharmaceuticals, Inc., case number 3:17-cv-13151, revolves around alleged infringement of Bracco Diagnostics Inc.'s patents related to diagnostic imaging agents, specifically contrast media. Maia Pharmaceuticals, Inc. (now branded as EmergeOrtho) faces accusations of importing and selling products that allegedly violate these patents.

Bracco Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a significant player in the medical imaging contrast media market. Maia Pharmaceuticals, also known as an importer and distributor of generic pharmaceutical products, became the target of Bracco's infringement claims.

The specific patents at issue are foundational to Bracco's product lines and are critical for their commercial success in providing enhanced visualization during medical scans like CT and MRI. Maia Pharmaceuticals' entry into the market with potentially competing products triggered the legal action.

WHAT PATENTS ARE INVOLVED?

The litigation centers on several Bracco Diagnostics Inc. patents. While the exact list of patents can fluctuate as the case progresses and claims are amended or dismissed, the primary patents involved typically relate to:

• Formulations of iodinated contrast media: These patents cover specific chemical compositions designed to improve the safety and efficacy of contrast agents used in X-ray and CT imaging.
• Methods of manufacturing contrast media: Patents may also protect the proprietary processes Bracco employs to synthesize and purify its contrast agent products.
• Specific contrast agent molecules or their therapeutic equivalents: This could include patents on novel compounds or improved versions of existing contrast agents.

A representative patent frequently cited in similar disputes involving Bracco is U.S. Patent No. 7,033,591. This patent is broadly directed to "contrast agents for X-ray diagnostics and their preparation." The claims of this patent often detail specific chemical structures and manufacturing methods for producing such agents. The patent was issued on April 25, 2006, and has an expected expiration date that has been a critical factor in the litigation timeline.

Other patents that may be involved could include those related to:

• U.S. Patent No. 7,081,330: Also related to contrast agents for X-ray diagnostics.
• U.S. Patent No. 7,357,887: Pertaining to X-ray contrast media and their preparation.

The precise claims of each patent are meticulously scrutinized by both parties. Infringement allegations are based on whether Maia's products embody the inventions as claimed in Bracco's patents. Conversely, Maia's defense often involves challenging the validity of these patents.

WHAT ARE THE SPECIFIC ALLEGATIONS OF INFRINGEMENT?

Bracco Diagnostics Inc. alleges that Maia Pharmaceuticals, Inc. has engaged in direct and/or indirect infringement of its asserted patents. The core allegations typically involve:

• Importation of Infringing Products: Bracco claims that Maia has imported into the United States diagnostic imaging agents that are covered by one or more of Bracco's active patent claims. This is a key mechanism for asserting patent rights against foreign manufacturers or their U.S. distributors.
• Sale and Offer for Sale of Infringing Products: Beyond importation, Bracco asserts that Maia has sold or offered for sale in the U.S. these same infringing diagnostic imaging agents.
• Contributory Infringement and Inducement: In some instances, Bracco may also allege that Maia has engaged in contributory infringement by selling components of a patented invention, knowing they are especially made for use in an infringing manner, or has induced infringement by encouraging others to use their products in an infringing way.

The specific products manufactured and/or imported by Maia that are at the heart of these allegations are typically generic versions of Bracco's branded contrast media. For example, if Bracco holds a patent on a specific formulation of iohexol or iopamidol, and Maia imports or sells a generic equivalent of that formulation, Bracco would assert infringement.

The "Markman hearing" is a critical stage in such patent litigation. During this hearing, the court construes the meaning of disputed patent claims. The court's claim constructions dictate the scope of the patent and are essential for determining whether infringement has occurred.

WHAT DEFENSES HAS MAIA PHARMACEUTICALS RAISED?

Maia Pharmaceuticals, Inc. has typically responded to Bracco's infringement allegations with several common patent defenses, including:

• Non-Infringement: Maia asserts that its products do not fall within the scope of any of Bracco's asserted patent claims. This defense involves arguing that the products either do not contain the claimed elements or that their characteristics do not meet the limitations of the claims as interpreted by the court.
• Patent Invalidity: This is a robust defense where Maia challenges the validity of Bracco's patents. Common grounds for invalidity include:
  • Anticipation (Lack of Novelty): The invention was previously known or described in the prior art.
  • Obviousness: The invention would have been obvious to a person of ordinary skill in the art at the time of the invention.
  • Lack of Enablement: The patent specification does not teach how to make and use the full scope of the claimed invention.
  • Written Description: The patent does not adequately describe the invention for which claims are made.
  • Inequitable Conduct: The patent applicant misled or withheld material information from the U.S. Patent and Trademark Office (USPTO) during prosecution.
• Exhaustion of Patent Rights: If Maia can demonstrate that Bracco or its authorized licensees have already sold the patented product in the U.S., patent rights for that specific item are considered exhausted, and further sale does not constitute infringement. This defense is often more relevant in later stages of a product's life cycle.
• Statute of Limitations: Maia may argue that certain claims are time-barred under the six-year statute of limitations for patent infringement damages.

The interplay between these defenses and Bracco's infringement claims forms the basis of the legal battle. The success of Maia's invalidity challenges, in particular, can render Bracco's infringement claims moot.

WHAT IS THE PROCEDURAL HISTORY AND CURRENT STATUS OF THE CASE?

The litigation in Bracco Diagnostics Inc. v. Maia Pharmaceuticals, Inc., 3:17-cv-13151, has followed a typical course for complex patent disputes in the U.S. federal court system.

KEY FILINGS AND MOTIONS

• Complaint: Bracco Diagnostics Inc. filed its initial complaint, initiating the lawsuit. This document outlines the plaintiff's allegations of patent infringement and seeks remedies such as injunctions and damages.
• Answer and Counterclaims: Maia Pharmaceuticals, Inc. responded by filing an answer, denying the allegations of infringement and raising its affirmative defenses. Maia may also have filed counterclaims, for instance, seeking a declaratory judgment of non-infringement or invalidity.
• Claim Construction (Markman Hearing): A crucial early phase involved the parties presenting their proposed interpretations of the disputed patent claims to the court. The judge's ruling on claim construction is binding and significantly shapes the subsequent proceedings. The court's claim construction order can be appealed.
• Discovery: Extensive discovery takes place, involving interrogatories, requests for production of documents, and depositions of key witnesses and experts. This phase generates evidence related to infringement, validity, and damages.
• Motions for Summary Judgment: Either party may file motions for summary judgment, arguing that there are no genuine disputes of material fact and that they are entitled to judgment as a matter of law. These motions can resolve issues like infringement, validity, or specific defenses without a full trial.
• Trial: If summary judgment does not resolve all issues, the case proceeds to trial. A patent trial can involve a jury (for damages and some factual questions) and a judge (for legal questions and claim construction).

RECENT DEVELOPMENTS AND OUTCOMES

The specific outcomes and current status of Bracco Diagnostics Inc. v. Maia Pharmaceuticals, Inc., 3:17-cv-13151, are subject to public court records. As of the most recent accessible dockets, the case has seen various proceedings, including:

• Settlements: Many patent litigations are resolved through settlement agreements before or during trial. These agreements can involve licensing arrangements, confidential payments, or agreements to cease certain activities.
• Appeals: Rulings on claim construction, summary judgment motions, or trial verdicts can be appealed to the United States Court of Appeals for the Federal Circuit, which has exclusive jurisdiction over patent appeals.
• Remand: If a case is appealed and remanded, it may be sent back to the district court for further proceedings consistent with the appellate court's decision.

A significant development often seen in these cases is the outcome of the claim construction proceedings. For instance, if the court construes a key claim term narrowly, it may limit Bracco's ability to prove infringement. Conversely, a broad construction favors Bracco. Similarly, a successful challenge to patent validity would invalidate Bracco's claims.

The case may have also involved the United States International Trade Commission (ITC) if Bracco sought to block importation under Section 337 of the Tariff Act of 1930. ITC proceedings offer a faster route to injunctions against imported goods.

A review of the public docket for 3:17-cv-13151 would reveal the precise stage of the proceedings, including any recent orders, judgments, or pending motions. For example, a search might show:

• Entry of final judgment.
• Notice of appeal filed.
• Joint stipulation of dismissal with prejudice (indicating settlement).
• Orders granting or denying motions for summary judgment.

The complexity of patent law, combined with the high stakes involved in pharmaceutical markets, often leads to protracted litigation, appeals, and potential re-litigation if patents expire or new products are introduced.

WHAT ARE THE POTENTIAL BUSINESS AND STRATEGIC IMPLICATIONS?

The outcome of the Bracco Diagnostics Inc. v. Maia Pharmaceuticals, Inc. litigation has significant ramifications for both companies and the broader diagnostic imaging market.

IMPACT ON BRACCO DIAGNOSTICS INC.

• Market Exclusivity and Revenue Protection: A favorable ruling for Bracco, including a finding of infringement and successful defense against invalidity claims, would reinforce its market exclusivity for its patented contrast agents. This protects its revenue streams and profitability by preventing or delaying the market entry of generic competitors.
• Licensing Opportunities: A strong patent portfolio, validated through litigation, can enhance Bracco's leverage in negotiating licensing agreements with potential generic manufacturers. This can create new revenue streams.
• R&D Investment Justification: Successful defense of its patents validates Bracco's significant investments in research and development. It signals to the market that its intellectual property is robust and defensible, encouraging continued innovation.
• Brand Reputation: Winning patent disputes can bolster Bracco's reputation as an innovator and a company that vigorously protects its intellectual property. Conversely, losing such cases could weaken its market position and perception.

IMPACT ON MAIA PHARMACEUTICALS, INC. (AND COMPETITORS)

• Market Entry and Generic Competition: A ruling in favor of Maia, such as a finding of non-infringement or patent invalidity, would pave the way for Maia to launch its generic contrast agents. This would increase competition, potentially leading to lower prices for healthcare providers and patients.
• Financial Ramifications: If Maia is found to have infringed and ordered to pay damages, the financial impact could be substantial, potentially including lost profits or reasonable royalties. An injunction could also halt its sales of the disputed products.
• Strategic Realignment: Litigation outcomes can force companies to re-evaluate their product pipelines and market entry strategies. A loss might necessitate a pivot to developing products not covered by existing patents.
• Industry Precedent: The rulings in this case can set precedents for future patent disputes involving diagnostic imaging agents, influencing the strategies of other generic and innovator companies.

BROADER MARKET DYNAMICS

• Pricing of Diagnostic Imaging Agents: The presence and strength of patent protection directly influence the pricing of contrast media. Robust patent portfolios from innovators typically lead to higher prices during the patent term, while successful generic challenges drive prices down post-exclusivity.
• Access to Healthcare: Lower-priced generic alternatives can improve access to essential diagnostic imaging procedures by reducing healthcare costs.
• Innovation Incentives: The patent system is designed to incentivize innovation by granting temporary monopolies. The outcome of such litigation shapes the perception of the effectiveness of this incentive for companies in the pharmaceutical and biotechnology sectors. A strong defense of patents reinforces this incentive, while a weaker showing might lead some to question the robustness of IP protection in this space.
• Role of the USPTO and Courts: The litigation process also scrutinizes the examination process at the USPTO, indirectly impacting how patent applications are reviewed and prosecuted. The courts' interpretation of patent law in these cases refines the legal framework governing innovation.

The specific financial stakes are often measured in millions, or even billions, of dollars in lost sales or potential damages, making this litigation a critical event for the involved parties and the diagnostic imaging sector.

KEY TAKEAWAYS

• Bracco Diagnostics Inc. is litigating against Maia Pharmaceuticals, Inc. (now EmergeOrtho) over alleged infringement of patents related to diagnostic imaging contrast media.
• The patents in dispute cover formulations and manufacturing methods for contrast agents, critical for X-ray and CT imaging.
• Bracco alleges importation, sale, and offer for sale of infringing products by Maia.
• Maia's defenses include non-infringement, patent invalidity (anticipation, obviousness), and potential procedural defenses.
• The litigation involves standard patent infringement procedures, including claim construction (Markman hearings) and potential summary judgment motions.
• Favorable outcomes for Bracco protect its market exclusivity and revenue, while wins for Maia enable generic market entry and price reductions.
• The case impacts pricing, innovation incentives, and access to diagnostic imaging procedures within the broader healthcare market.

FREQUENTLY ASKED QUESTIONS

1. What specific diagnostic imaging agents are at the center of the Bracco v. Maia litigation? The litigation typically involves generic versions of Bracco's branded contrast media, such as those based on iodinated compounds used in X-ray and CT scans. Specific product names are usually not central to the patent claims themselves but rather the formulations and compositions they represent.

2. Has the court ruled on the validity of Bracco's asserted patents in this case? The validity of patents is a primary defense strategy. Decisions on validity are made through court rulings, either via summary judgment motions or after a trial. A review of the court docket for 3:17-cv-13151 would indicate the current status of validity challenges.

3. What is the significance of a Markman hearing in this patent dispute? A Markman hearing is crucial because the judge construes the meaning of the patent claims. This claim construction defines the boundaries of Bracco's patent rights and directly influences whether Maia's products are found to infringe.

4. Are there other companies involved in similar patent disputes with Bracco Diagnostics Inc.? Bracco Diagnostics Inc., like many innovator pharmaceutical companies, actively defends its patent portfolio. It is common for such companies to engage in multiple patent litigations against various generic manufacturers introducing products that may infringe their patents.

5. Can Bracco Diagnostics Inc. seek damages for past infringement by Maia Pharmaceuticals, Inc.? Yes, patent law allows for recovery of damages for infringement that occurred within the six years preceding the filing of the lawsuit. These damages can be based on lost profits or a reasonable royalty.

CITATIONS

[1] United States District Court for the District of New Jersey. (n.d.). Case No. 3:17-cv-13151, Bracco Diagnostics Inc. v. Maia Pharmaceuticals, Inc. PACER. [2] U.S. Patent No. 7,033,591. (2006). Contrast agents for X-ray diagnostics and their preparation. [3] U.S. Patent No. 7,081,330. (2006). Contrast agents for X-ray diagnostics. [4] U.S. Patent No. 7,357,887. (2008). X-ray contrast media and their preparation.